Seven Eight Capital’s Esperion Therapeutics ESPR Stock Holding History

Seven Eight Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-18,941	Closed	-$704K	–	473
2020 Q3	$704K	Buy	+18,941	New	+$750K	0.15%	258
2018 Q4	–	Sell	-8,707	Closed	-$386K	–	583
2018 Q3	$386K	Sell	8,707 -13,600	-61%	-$624K	0.02%	485
2018 Q2	$874K	Buy	+22,307	New	+$1.13M	0.06%	303
2017 Q4	–	Sell	-23,398	Closed	-$1.17M	–	487
2017 Q3	$1.17M	Buy	23,398 +21,531	+1,153%	+$1.04M	0.14%	227
2017 Q2	$86K	Buy	+1,867	New	+$68.7K	0.01%	445
2015 Q2	–	Sell	-3,500	Closed	-$324K	–	563
2015 Q1	$324K	Buy	+3,500	New	+$226K	0.54%	49

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Seven Eight Capital's ESPR Position: Q4 2020 in Review

Seven Eight Capital sold out of Esperion Therapeutics (ESPR) in Q4 2020, closing a stake of 18,941 shares — an estimated $704K sold.

Seven Eight Capital first reported a position in ESPR in Q1 2015 and held it in 6 quarters. The position peaked at $1.17M in Q3 2017. 157 funds tracked by Wall St. Rank hold ESPR as of Q4 2020.

Seven Eight Capital reported no remaining Esperion Therapeutics position as of Q4 2020 after selling out during the quarter.
Seven Eight Capital sold 18,941 Esperion Therapeutics shares in Q4 2020, an estimated $704K.
Seven Eight Capital first reported a position in Esperion Therapeutics in Q1 2015 and held it in 6 quarters.
Seven Eight Capital's Esperion Therapeutics position peaked at $1.17M in Q3 2017.
157 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2020.

Based on Seven Eight Capital's 13F filing for Q4 2020, filed 9 Feb 2021.